Relay Therapeutics reported first Phase 2 efficacy data for its PI3Kα inhibitor zovegalisib in a vascular anomalies study, saying the results cleared Wall Street expectations and expanding the program beyond Relay’s earlier breast-cancer narrative. The dataset is positioned as the first meaningful readout for the rare genetic disease population. Management also described the effect as supportive of moving zovegalisib into a broader R&D frame for vascular anomaly indications, a category with limited approved options and high unmet need. The new data follows earlier company messaging around potential superiority versus existing approaches in vascular anomalies.